Flerie has been approved for listing on Nasdaq Stockholm and publishes its prospectus

About the list change

The first day of trading on the Nasdaq Stockholm main market is scheduled for Thursday 27 June 2024. The shares will be traded in the Mid Cap segment under the same ticker (FLERIE) and ISIN code (SE0008966295). There will not be any offer or issue of new shares in connection with the list change. Shareholders of Flerie will not need to take any action in connection with the list change. The last day of trading in Flerie’s shares on Nasdaq First North Growth Market is scheduled for today, Wednesday 26 June 2024. Furthermore, the Company's board of directors will decide on the record date for the previously communicated reverse share split after the list change has been completed. More information about the reverse share split will be published in a separate press release.

“The listing on the Nasdaq Stockholm main market entails increased credibility and awareness, which will be beneficial for us in order to attract important investments and partnerships for our portfolio companies. This uplisting and the subsequent reverse share split concludes the setup of a new kind of investment model that is Flerie. We’re pioneering long-term company building within the biotech and pharma sector, while investors globally have access to and can trade in our shares via one of Europe’s most reputable stock exchanges.”, says Ted Fjällman, CEO of Flerie.

The Prospectus

For complete information about the expected list change from the Nasdaq First North Growth Market to the Nasdaq Stockholm main market, please refer to the Prospectus that has been prepared by Flerie and as of today has been approved and registered by the SFSA. The Prospectus is available on Flerie’s website (www.flerie.com) and will also be available on the SFSA's website (www.fi.se).

The Prospectus has been prepared as a simplified prospectus in accordance with Article 14 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the “Prospectus Regulation”). The SFSA, as the Swedish national competent authority, has approved the Prospectus in accordance with Article 20 of the Prospectus Regulation. The SFSA only approves the Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of the Company or of the securities described in the Prospectus. The SFSA does not guarantee the accuracy or completeness of the factual information contained in the Prospectus. Each investor is advised to make its own assessment of whether it is appropriate to invest in the Company's shares.

Advisor

Setterwalls Advokatbyrå is the legal advisor to Flerie in connection with the listing on Nasdaq Stockholm.

For more information:

Ted Fjällman, CEO of Flerie
E-mail: ir@flerie.com

The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CEST on 26 June 2024.

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie is listed on Nasdaq First North Growth Market with the ticker FLERIE. Redeye is the company’s Certified Adviser. For further information please visit www.flerie.com.